Treatment of IL-17 mediated disease by blocking SEFIR-SEFIR interactions
US9611295B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 29, 2012 |
| Grant date | Apr 4, 2017 |
| Priority date | — |
| Expiry date | Oct 29, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to the SEFIR domain of Act1. In particular, it has been determined that the αC helix region of the SEFIR domain of both IL-17R and Act1 plays an important role in the association of IL-17R and Act1. To facilitate cell permeation, the decoy peptide is preferably conjugated to a protein transduction domain. Examples of IL-17 mediated diseases include various human and animal inflammatory and autoimmune diseases such as asthma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.